New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study.

Autor: Carrión-Nessi FS; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela.; 'Luis Razetti' School of Medicine, Central University of Venezuela, Caracas, Venezuela., Ascanio LC; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA., Pineda-Arapé AG; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela., Omaña-Ávila ÓD; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela.; 'Luis Razetti' School of Medicine, Central University of Venezuela, Caracas, Venezuela., Mendoza-Millán DL; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela.; 'Luis Razetti' School of Medicine, Central University of Venezuela, Caracas, Venezuela., Romero SR; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.; Medical Scientist Training Program (MD/PhD), University of Minnesota Medical School, Minneapolis, MN, USA., Almao-Rivero AB; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela., Camejo-Ávila NA; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela., Gebran-Chedid KJ; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela., Rodriguez-Saavedra CM; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela., Freitas-De Nobrega DC; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela., Castañeda SA; Centro de Investigaciones en Microbiología y Biotecnología, Facultad de Ciencias Naturales, Universidad del Rosario (CIMBIUR), Universidad del Rosario, Bogotá, Colombia., Forero-Peña JL; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela., Delgado-Noguera LA; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela., Meneses-Ramírez LK; 'Dr. Francisco Battistini Casalta' Health Sciences School, University of Oriente - Bolivar Nucleus, Ciudad Bolivar, Venezuela., Cotuá JC; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela., Rodriguez-Morales AJ; Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon.; Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru., Forero-Peña DA; Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela. vacter.cv@gmail.com.; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela. vacter.cv@gmail.com.; 'Luis Razetti' School of Medicine, Central University of Venezuela, Caracas, Venezuela. vacter.cv@gmail.com.; Infectious Diseases Department, University Hospital of Caracas, Caracas, Venezuela. vacter.cv@gmail.com., Paniz-Mondolfi AE; Department of Infectious Diseases and Tropical Medicine, Venezuelan Science Incubator, Barquisimeto, Venezuela. alberto.paniz-mondolfi@mountsinai.org.; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. alberto.paniz-mondolfi@mountsinai.org.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2023 Dec 14; Vol. 23 (1), pp. 877. Date of Electronic Publication: 2023 Dec 14.
DOI: 10.1186/s12879-023-08898-2
Abstrakt: Background: Persistent headache is a frequent symptom after coronavirus disease 2019 (COVID-19) and there is currently limited knowledge about its clinical spectrum and predisposing factors. A subset of patients may be experiencing new daily persistent headache (NDPH) after COVID-19, which is among the most treatment-refractory primary headache syndromes.
Methods: We conducted a cross-sectional study in Latin America to characterize individuals with persistent headache after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify factors associated with NDPH. Participants over 18 years old who tested positive for SARS-CoV-2 infection and reported persistent headache among their symptoms completed an online survey that included demographics, past medical history, persistent headache clinical characteristics, and COVID-19 vaccination status. Based on participants' responses, NDPH diagnostic criteria were used to group participants into NDPH and non-NDPH groups. Participant data was summarized by descriptive statistics. Student's t and Mann-Whitney U tests were used according to the distribution of quantitative variables. For categorical variables, Pearson's chi-square and Fisher's exact tests were used according to the size of expected frequencies. Binomial logistic regression using the backward stepwise selection method was performed to identify factors associated with NDPH.
Results: Four hundred and twenty-one participants from 11 Latin American countries met the inclusion criteria. One in four participants met the NDPH diagnostic criteria. The mean age was 40 years, with most participants being female (82%). Over 90% of the participants reported having had mild/moderate COVID-19. Most participants had a history of headache before developing COVID-19 (58%), mainly migraine type (32%). The most predominant clinical characteristics in the NDPH group were occipital location, severe/unbearable intensity, burning character, and radiating pain (p < 0.05). A higher proportion of anxiety symptoms, sleep problems, myalgia, mental fog, paresthesia, nausea, sweating of the face or forehead, and ageusia or hypogeusia as concomitant symptoms were reported in participants with NDPH (p < 0.05). Palpebral edema as a concomitant symptom during the acute phase of COVID-19, occipital location, and burning character of the headache were risk factors associated with NDPH.
Conclusion: This is the first study in Latin America that explored the clinical spectrum of NDPH after SARS-CoV-2 infection and its associated factors. Clinical evaluation of COVID-19 patients presenting with persistent headache should take into consideration NDPH.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje